ACADIA Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Remlifanserin is advancing in robustly designed trials for Alzheimer's and Lewy body dementia psychosis, with a focus on improved efficacy, safety, and regulatory alignment. The phase II readout is expected between August and October, while a novel R-ketamine asset is progressing in MDD.
-
Strong commercial growth and robust financials support ongoing investment in a diverse pipeline, with key catalysts including the remlifanserin phase II readout and new DAYBUE formulation. Expansion efforts target both US and international markets, despite regulatory challenges.
-
Management projects $1.7B in 2028 sales, driven by NUPLAZID and DAYBUE, with new formulations and expanded field force fueling growth. Remlifanserin phase II data is expected by fall, and regulatory reexamination for DAYBUE in Europe will include patient advocacy.
-
The conference highlighted robust commercial growth for NUPLAZID and DAYBUE, ambitious global expansion, and a diversified pipeline with multiple late-stage milestones expected by 2027. AI-driven innovation and targeted business development underpin the strategy for sustained growth.
Fiscal Year 2025
-
Adjusted revenues grew 14% to $1.08B in 2025, with NUPLAZID and DAYBUE both posting double-digit sales growth. 2026 guidance projects continued strong momentum, supported by new product launches, expanded field teams, and a robust R&D pipeline.
-
Strong commercial growth for NUPLAZID and DAYBUE is supported by renewed investments and expanded field force, with both products showing robust patient retention and market penetration. Key pipeline assets, including ACP-204 for ADP and LBDP, are advancing, and the company maintains a strong financial position with growing profitability.
-
Aiming for global leadership in neurological and rare diseases, the company projects over $1 billion in 2025 revenue, driven by NUPLAZID and DAYBUE, and expects major pipeline milestones—including ACP-204 and DAYBUE regulatory decisions—by 2026. Expansion into new therapeutic areas and global markets is underway.
-
Nuplazid and Daybue are on track for over $1 billion in annual revenue, with Nuplazid's sales force expanding 30% in January and Daybue seeing record referrals after its own expansion. The pipeline remains robust, led by ACP-204 in Phase II for Alzheimer's and Lewy body dementia psychosis.
-
Q3 2025 revenues rose 11% year-over-year to $278.6M, with DAYBUE and NUPLAZID both posting record sales and strong prescription growth. Strategic investments in salesforce expansion and R&D are expected to drive continued momentum, with updated 2025 guidance reflecting this strength.
-
Key updates include an imminent phase 3 readout for ACP-101 in Prader-Willi syndrome, ongoing phase 2/3 trials for ACP-204 in Alzheimer’s and Lewy body psychosis, and the upcoming phase 2 start for ACP-211 in MDD. The pipeline strategy emphasizes rare diseases and neuropsychiatry.
-
DAYBUE has achieved strong penetration in COEs and is expanding in the community, with international launches planned for 2026. NUPLAZID growth is driven by renewed awareness campaigns, while pipeline investments are guided by data and financial flexibility, targeting both neurology and rare disease.
-
The conference highlighted robust commercial growth for key products, strategic expansion in both field force and global reach, and a strong, diversified pipeline with multiple near-term clinical milestones. Leadership emphasized disciplined investment, operating leverage, and a focus on innovation and patient needs.
-
Strong commercial performance for DAYBUE and NUPLAZID, with robust patient persistency and expanding field force. Pipeline progress includes upcoming phase III and II readouts for ACP-101 and ACP-204. Ex-U.S. expansion and business development remain key priorities.
-
Q2 2025 revenue grew 9% year-over-year to $264.6 million, led by strong DAYBUE and NUPLAZID sales. Persistency and community uptake for DAYBUE improved, while NUPLAZID saw record shipments and DTC-driven growth. Pipeline progress and raised guidance reflect continued momentum.
-
A robust pipeline of nine disclosed programs, including five key late-stage assets, is advancing in neurology and rare diseases, supported by strong commercial brands and disciplined R&D investment. Multiple clinical milestones and global expansion are expected through 2027, with risk-adjusted peak sales potential up to $12 billion.
-
Leadership changes and commercial strategy shifts have accelerated clinical programs and driven strong growth for Nuplazid and Daybue. Patent wins secure exclusivity, while pipeline expansion and international launches are underway. Financial strength supports ongoing business development.
-
Management reported no immediate macro or regulatory risks, with DAYBUE’s U.S. relaunch showing early signs of renewed growth after a sales force expansion. NUPLAZID’s awareness campaign is driving steady gains, and key pipeline programs are on track for major data readouts later this year.
-
Q1 2025 revenue grew 19% year-over-year to $244.3M, driven by strong DAYBUE and NUPLAZID sales. Persistency and patient growth improved, and the pipeline advanced with accelerated COMPASS PWS trial timelines. Full-year guidance was reiterated, with increased R&D spend.
-
Revenue from two commercial products is projected to surpass $1 billion in 2025, with significant growth initiatives underway for Daybue and Nuplazid. Pipeline progress includes late-stage trials for Alzheimer's disease psychosis and Prader-Willi syndrome, and European expansion is advancing with regulatory submissions.
-
Two neuroscience products are on track for over $1B in 2024, with Daybue’s growth expected to accelerate in the second half as field force expansion targets community physicians. International launches and a robust late-stage pipeline support future growth, while a strong balance sheet enables broader rare disease business development.
-
Revenue for 2025 is guided above $1 billion, driven by NUPLAZID and DAYBUE, with growth expected from expanded sales efforts and new marketing strategies. DAYBUE’s persistency and patient support are strong, while European and Canadian launches are planned for next year. Patent litigation continues, and pipeline assets show promising early data.
-
Sales force expansion and new education programs aim to boost Daybue growth, especially outside COEs. Daybue’s EU launch is progressing with managed access programs in key countries, while pipeline assets ACP-204 and ACP-101 advance in clinical trials. Nuplazid’s targeted DTC campaign is driving strong growth.
-
Leadership outlined a vision for surpassing $1 billion in 2025 net sales, driven by NUPLAZID and DAYBUE, with DAYBUE's European expansion and pipeline progress in Prader-Willi, Alzheimer's psychosis, and essential tremor. Strong cash reserves support both internal R&D and external growth.
Fiscal Year 2024
-
Record 2024 revenue growth driven by Daybue and Nuplazid, with 2025 guidance above $1 billion. Pipeline expansion, international launches, and strong cash position support long-term growth, while regulatory and payer changes present ongoing risks.
-
A commercial-stage biotech highlighted strong financials, robust growth for Daybue and Nuplazid, and a promising late-stage pipeline. Strategic business development and efficient marketing are driving expansion, with key catalysts expected in 2025.
-
Leadership outlined a strategy to expand commercial growth for Nuplazid and Daybue, with Daybue's EU launch targeted for early 2026 and ongoing efforts to support patient retention. The pipeline includes late-stage assets for Alzheimer’s psychosis and Prader-Willi syndrome, and the company remains cash flow positive with strong IP protection.
-
Q3 2024 net sales rose 18% year-over-year, driven by strong growth in DAYBUE and NUPLAZID, both tracking to over $1 billion in annualized sales. Guidance for 2024 was raised, with continued expansion and pipeline progress expected in 2025.
-
A neuroscience and rare disease-focused biotech is driving growth with Nuplazid and Daybue, supported by strong real-world data, robust IP, and new awareness campaigns. Late-stage pipeline assets and ex-U.S. expansion are underway, with a solid cash position and active business development.
-
The company is advancing its rare disease and neuropsychiatric franchises, with Daybue showing strong early adoption and global expansion plans. Pipeline progress includes ACP-204 for Alzheimer's psychosis and ACP-101 for Prader-Willi syndrome, while Nuplazid benefits from new evidence and awareness campaigns.
-
Daybue has reached 30% of diagnosed Rett patients, with strong COE penetration and ongoing expansion into broader practice settings. Nuplazid’s growth is driven by real-world evidence and label clarification, with new campaigns expected to further boost demand. Cash flow remains robust, and the company is well-positioned for rare disease asset acquisitions.
-
Q2 2024 revenues rose 46% year-over-year to $242M, led by DAYBUE and NUPLAZID. NUPLAZID guidance was raised to $590–$610M, while DAYBUE was lowered to $340–$370M due to slower patient growth. Cash balance exceeds $500M, supporting pipeline and commercial expansion.